Supplementary Table 2. Search strategy in MEDLINE through PubMed

1.	Metformin[Mesh:NoExp] OR metformin[TW] OR metformine[TW] OR LA-6023[TW] OR LA6023[TW]
2.	Sulfonylurea Compounds [Mesh:NoExp] OR sulfonylurea[TW]
3.	glimepiride[NM] OR glimepiride[TW] OR HOE-490[TW] OR HOE490[TW]
4.	Gliclazide[MH] OR gliclazide[TW] OR S-1702[TW] OR S1702[TW] OR S-852[TW] OR S852[TW]
5.	Glipizide[MH] OR glipizide[TW] OR K-4024[TW] OR K4024[TW]
6.	Glyburide[MH] OR glybenclamide[TW] OR glyburide[TW] OR HB-419[TW] OR HB419[TW] OR HB-420[TW] OR HB420[TW]
7.	Thiazolidinediones[Mesh:NoExp] OR thiazolidinediones[TW]
8.	Pioglitazone[MH] OR pioglitazone[TW] OR U-72107A[TW] OR U72107A[TW] OR AD-4833[TW] OR AD4833[TW]
9.	Rosiglitazone[MH] OR rosiglitazone[TW] OR BRL-49653[TW] OR BRL49653[TW]
10.	lobeglitazone[NM] OR lobeglitazone[TW] OR CKD-501[TW] OR CKD501[TW]
11.	Dipeptidyl-Peptidase IV Inhibitors [MH] OR "dipeptidyl-peptidase IV inhibitor*"[TW] OR "DPP-4 Inhibitor*"[TW]
12.	Sitagliptin Phosphate[MH] OR sitagliptin[TW] OR sitagliptine[TW] OR MK-0431[TW] OR MK0431[TW]
13.	Vildagliptin[MH] OR vildagliptin[TW] OR NVP-LAF237[TW] OR NVPLAF237[TW]
14.	Linagliptin[MH] OR linagliptin[TW] OR BI-1356[TW] OR BI1356[TW]
15.	saxagliptin[NM] OR saxagliptin[TW] OR BMS-477118[TW] OR BMS477118[TW]
16.	alogliptin[NM] OR alogliptin[TW] OR SYR-322[TW] OR SYR322[TW]
17.	anagliptin[NM] OR anagliptin[TW] OR SK-0403[TW] OR SK0403[TW]
18.	LC15-0444[NM] OR gemigliptin[TW] OR LC15-0444[TW] OR LC150444[TW]
19.	"4-(3-amino-4-(2,4,5-trifluorophenyl)butanoyl)-3-(tert-butoxymethyl)piperazin-2-one" [Supplementary Concept] OR evogliptin[TW] OR DA-1229[TW] OR DA1229[TW]
20.	"3-(4-(4-(3-methyl-1-phenyl-1H-pyrazol-5-yl)piperazin-1-yl)pyrrolidin-2-ylcarbonyl)thiazolidine" [Supplementary Concept] OR teneligliptin[TW] OR mp-513[TW] OR mp513[TW]
21.	Glucagon-Like Peptide 1 [Mesh:NoExp] "glucagon-like peptide-1"[TW] OR GLP-1[TW] OR GLP1[TW]
22.	Exenatide[MH] OR exenatide[TW] OR AC-2993[TW] OR AC2993[TW] OR ITCA-650[TW] OR ITCA650[TW]
23.	dulaglutide[NM] OR dulaglutide[TW] OR LY-2189265[TW] OR LY2189265[TW]
24.	lixisenatide[TW] OR AVE-010[TW] OR AVE010[TW] OR AVE-0010[TW] OR AVE0010[TW] OR AQVE-10010[TW] OR AQVE10010[TW] OR ZP-10[TW] OR ZP10[TW]
25.	Liraglutide[MH] OR liraglutide[TW] OR NN-2211[TW] OR NN2211[TW]
26.	semaglutide[TW] OR NN-9535[TW] OR NN9535[TW] OR NN-9924[TW] OR NN9924[TW]
27.	Sodium-Glucose Transporter 2 Inhibitors [MH] OR "sodium-glucose transporter 2 inhibitor*"[TW] OR "SGLT2 Inhibitor*"[TW] OR "SGLT2 Inhibitor*"[TW]
28.	dapagliflozin[NM] OR dapagliflozin[TW] OR BMS-512148[TW] OR BMS512148[TW]
29.	Canagliflozin[MH] OR canagliflozin[TW] OR JNJ-28431754[TW] OR JNJ28431754[TW] OR TA-7284[TW] OR TA7284[TW]
30.	empagliflozin[NM] OR empagliflozin[TW] OR BI-10773[TW] OR BI10773[TW]
31.	ertugliflozin[NM] OR ertugliflozin[TW] OR PF-04971729[TW] OR PF04971729[TW]
32.	Ipragliflozin[NM] OR Ipragliflozin[TW] OR ASP-1941[TW] OR ASP1941[TW]
33.	Enavogliflozin[Supplementary Concept] OR enavogliflozin[TW] OR DWP-16001[TW] OR DWP16001[TW]
34.	1-33/OR
35.	33 AND (Randomized Controlled Trial[PT] OR Controlled Clinical Trial[PT:NoExp] OR randomised[TIAB] OR randomized[TIAB] OR placebo*[TIAB] OR Clinical Trials as Topic[Mesh:NoExp] OR randomly[TIAB] OR trial*[TI]) NOT (Case Reports[PT] OR case report*[TI] OR Comment[PT] OR comment*[TI] OR Letter[PT] OR letter[TI] OR Editorial[PT] OR (Animals[MeSH] NOT Humans[MeSH]))
36.	34 NOT Meta-Analysis[PT] OR metaanalys*[TI] OR meta-analys*[TI] OR Systematic Review[PT] OR systematic-review*[TI]